Novanta Inc. (NOVT) 2025 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2025. Novanta Inc. is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers (OEMs). The company operates through two reportable segments: Automation Enabling Technologies (laser beam steering, robotics, precision motion) and Medical Solutions (insufflators, imaging, RFID, motion control). The company is incorporated in Canada but maintains its principal executive offices in Bedford, Massachusetts.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $980.6 million | $949.2 million |
| Gross Profit | $435.3 million | $421.5 million |
| Gross Margin | 44.4% | 44.4% |
| Operating Income | $94.0 million | $110.6 million |
| Net Income | $53.8 million | $64.1 million |
| Diluted EPS | $1.47 | $1.77 |
| Operating Cash Flow | $64.1 million | $158.5 million |
| Cash and Equivalents (Year End) | $380.9 million | $114.0 million |
| Total Debt Outstanding | $259.6 million | $416.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 3.3% year-over-year, driven by the 2025 acquisition of Keonn Technologies ($21.8 million contribution) and growth in the Automation Enabling Technologies segment. This was partially offset by a decline in the Medical Solutions segment excluding the acquisition.
- Profitability Decline: Operating income decreased 15.0% to $94.0 million. This was primarily due to a $19.7 million increase in SG&A expenses (driven by ERP system implementation planning and insurance recovery claims), an $8.9 million increase in restructuring/acquisition costs, and higher amortization.
- EPS Reduction: Diluted EPS fell to $1.47 from $1.77, reflecting lower operating income, partially offset by reduced interest expense due to lower average debt levels.
- Segment Performance:
- Automation Enabling Technologies: Revenue up 2.1% to $500.8 million; Operating income up to $114.5 million.
- Medical Solutions: Revenue up 4.6% to $479.8 million; Operating income down to $51.2 million due to higher SG&A and restructuring costs.
Guidance, Outlook, and Risks
Recent Capital Actions:
- Tangible Equity Units (TEUs): In November 2025, the company issued 12.65 million TEUs, raising net proceeds of $613.1 million. Each unit consists of a prepaid stock purchase contract and a senior amortizing note (6.30% interest, maturing 2028).
- Debt Facility: In June 2025, the company entered a Fourth Amended and Restated Credit Agreement providing a $1.0 billion facility (Term loans + $850 million revolver). As of year-end, $149.0 million was outstanding under term loans, with no revolver borrowings.
- Acquisition: Acquired Keonn Technologies (RFID solutions) in April 2025 for approximately $71.0 million net of cash, with up to $21.9 million in contingent consideration.
Outlook and Strategy: Management continues to focus on increasing medical sales as a percentage of total revenue and penetrating high-growth advanced industrial applications. The company is executing a regionalized manufacturing strategy to improve efficiency, which has temporarily impacted margins and increased inventory levels.
Risks and Contingencies:
- Macroeconomic Factors: Exposure to inflation, supply chain disruptions, and geopolitical tensions (including tariffs and trade policies).
- Customer Concentration: Two OEM customers represented approximately 12% and 11% of consolidated revenue in 2025.
- Regulatory: Significant exposure to FDA and EU medical device regulations, including the new EU Medical Devices Regulation and UK post-Brexit requirements.
- Cybersecurity: Ongoing risk of cyberattacks targeting IT systems and confidential data.
Investor Verification Checklist
- TEU Settlement Terms: Verify the settlement mechanics of the 6.50% Tangible Equity Units, specifically the share issuance range (0.3729 to 0.4662 shares per unit) based on the stock price in November 2028.
- Restructuring Costs: Monitor the execution of the 2025 restructuring program (expected total cost ~$25.0 million) and its impact on future operating margins.
- ERP Implementation: Assess the progress and cost implications of the financial and operational system implementation, which drove a significant portion of the SG&A increase.
- Keonn Integration: Track the performance of the Keonn Technologies acquisition against the revenue targets required to trigger the $21.9 million contingent consideration.
- Debt Covenants: Confirm continued compliance with the leverage ratio (max 3.75:1.00) and fixed charge coverage ratio (min 1.25:1.00) under the new credit facility.